Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma

Background/aims.  The prognosis of hepatocellular carcinoma (HCC) on cirrhosis is hard to predict as it depends on tumour stage, underlying liver disease, type of treatment and, possibly, biological factors of the tumour itself.

[1]  I. Sheen,et al.  Is the expression of γ-glutamyl transpeptidase messenger RNA an indicator of biological behavior in recurrent hepatocellular carcinoma? , 2003 .

[2]  G. Klintmalm,et al.  Liver transplantation in association with hepatocellular carcinoma: An update of the international tumor registry , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  L. Qin,et al.  The prognostic molecular markers in hepatocellular carcinoma. , 2002, World journal of gastroenterology.

[4]  T. Livraghi.  Role of Percutaneous Ethanol Injection in the Treatment of Hepatocellular Carcinoma , 2002, Digestive Diseases.

[5]  K. Batts,et al.  Prognostic Histologic Indicators of Curatively Resected Hepatocellular Carcinomas: A Multi-institutional Analysis of 425 Patients With Definition of a Histologic Prognostic Index , 2002, The American journal of surgical pathology.

[6]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[7]  B. Sangro,et al.  Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[8]  H. Bertani,et al.  Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors , 2001, British Journal of Cancer.

[9]  F. Farinati,et al.  Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective? , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[10]  F. Farinati,et al.  How should patients with hepatocellular carcinoma be staged? , 2000, Cancer.

[11]  J. Bruix,et al.  Prospective Validation of the Cancer of the Liver Italian Program (CLIP) Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma , 2000, Hepatology.

[12]  T. Seki,et al.  Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. , 2000, International journal of molecular medicine.

[13]  Bernardino,et al.  Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma , 2000, Hepatology.

[14]  M. Monden,et al.  Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma , 1999, British Journal of Cancer.

[15]  H. Fukuda,et al.  Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. , 1998, Hepato-gastroenterology.

[16]  S. Pignata,et al.  Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial , 1998, The Lancet.

[17]  J. Bruix,et al.  Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution , 1998, Hepatology.

[18]  L. Qin,et al.  Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. , 1998, Chinese medical journal.

[19]  A. Puisieux,et al.  TP53 and hepatocellular carcinoma. , 1997, Pathologie-biologie.

[20]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[21]  G. Wu,et al.  Hepatocellular carcinoma: update on diagnosis and treatment. , 1995, Digestive diseases.

[22]  M. Colombo,et al.  Epidemiology of hepatocellular carcinoma. , 1995, The Italian journal of gastroenterology.

[23]  G. Tytgat,et al.  Hepatobiliary and Pancreatic Malignancies: Diagnosis, Medical, and Surgical Management , 1989 .

[24]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[25]  S. Futagawa,et al.  The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas , 2006, Surgery Today.

[26]  I-ShyanSheen,et al.  Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma , 2003 .

[27]  J. Bruix,et al.  Prognosis of hepatocellular carcinoma. , 2002, Hepato-gastroenterology.

[28]  Bellia Mario,et al.  Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80) , 2000 .

[29]  J. Figueras,et al.  A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization , 2000, Cancer.

[30]  K. Endo,et al.  Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. , 2000, Journal of hepatology.

[31]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.

[32]  K. Ishak,et al.  Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. , 1996, American journal of clinical pathology.